1357920-84-3

Basic information

• Product Name: Belizatinib
• Synonyms: Belizatinib;Belizatinib (TSR011);TSR-011
• CAS NO: 1357920-84-3
• Molecular Formula: C₃₃H₄₄FN₅O₃
• Molecular Weight: 577.7325632
• Mol File: 1357920-84-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Belizatinib(CAS DataBase Reference)
• NIST Chemistry Reference: Belizatinib(1357920-84-3)
• EPA Substance Registry System: Belizatinib(1357920-84-3)

Safety Data

• Hazardous Substances Data: 1357920-84-3(Hazardous Substances Data)

Usage

Description

Different sources of media describe the Description of 1357920-84-3 differently. You can refer to the following data:
1. Belizatinib, also known as TSR-011, is an oral inhibitor of ALK and TRK.
2. Belizatinib is an inhibitor of anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases A/B/C (IC50s = 0.7 and <3 nM, respectively).

Uses

Belizatinib is used in treating diseases via targeted modulation of gene signaling networks.

Upstream product

• 78225-74-8 4-fluorobenzoyl isothiocyanate 
• 403-43-0 4-fluorobenzoyl chloride 
• 1357924-77-6 (1s,4s)-4-(2-amino-5-(hydroxymethyl)phenylamino)-N-isopropylcyclohexanecarboxamide 
• 1357920-83-2 (E)-4-fluoro-N-(6-(hydroxymethyl)-1-( (1s,4s)-4-(isopropylcarbamoyl)cyclohexyl)-1H-benzo[d]imidazol-2(3H)-ylidene)benzamide 
• 1357923-26-2 C₁₀H₂₀N₂O*ClH 
• 1357923-28-4 (1s,4s)-4-((5-(hydroxymethyl)-2-nitrophenyl)amino)-N-isopropylcyclohexanecarboxamide 
• 503315-74-0 (3-fluoro-4-nitrophenyl)methanol 
• 22990-34-7 2-(piperidin-4-yl)propan-2-ol 

Relevant articles and documents

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer

A class of 2-acyliminobenzimidazoles has been developed as potent and selective inhibitors of anaplastic lymphoma kinase (ALK). Structure based design facilitated the rapid development of structure-activity relationships (SAR) and the optimization of kinase selectivity. Introduction of an optimally placed polar substituent was key to solving issues of metabolic stability and led to the development of potent, selective, orally bioavailable ALK inhibitors. Compound 49 achieved substantial tumor regression in an NPM-ALK driven murine tumor xenograft model when dosed qd. Compounds 36 and 49 show favorable potency and PK characteristics in preclinical species indicative of suitability for further development.